Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press113810.17650/1726-9776-2007-3-4-44-48DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железыIndividual estimation of the level of prostatic specific antigen in patients with prostate cancer after brachytherapyИндивидуальная оценка уровня простатического специфического антигена у больных раком предстательной железы после брахитерапииMinayevaN. G.МинаеваН. Г.
Russian Federation

Obninsk

Обнинск

SviridovP. V.СвиридовП. В.
Russian Federation

Obninsk

Обнинск

KaryakinO. B.КарякинО. Б.
Russian Federation

Obninsk

Обнинск

ParshovYe. M.ПаршковЕ. М.
Russian Federation

Obninsk

Обнинск

Medical Radiology Research Center, Russian Academy of Medical SciencesГУ Медицинский радиологический научный центр РАМН301220073444481602202016022020https://oncourology.abvpress.ru/oncur/article/view/1138

The study covered 44 patients with localized and locally advanced prostate cancer (PC), who were followed up for at least 18 months after brachytherapy. A significant reduction in the level of prostatic specific antigen (PSA) in the blood of patients was observed 3 months after brachytherapy and tended to decrease further during a 12-month follow-up. It is the time after brachytherapy that may be considered as a criterion for a primary tumor response to the therapy. There were individual differences in the velocity and decrease rate of PSA levels during the therapy: in 30 (68.2%) patients, PSA values were in the range of 0.01—0.98 ng/ml (mean 0.39±0.31 ng/ml) while in 14 (31.8%) patients, those were 1.10—6.20 ng/ml (3.02±1.79 ng/ml). A certain correlation was found between the parameters of PSA (baseline PSA level, time course of changes, and kinetics of PSA levels) and the outcome of the disease. A more objective evaluation of the efficiency may be made after increasing the time of a follow-up and the number of patients after brachytherapy.

.

1. Catalona W., Smith D., Ratliff T. et al. Measurement of prostate-specific antigen in serum a screening test for prostate cancer. N Engl J Med 1991;324: 1156—61.Catalona W., Smith D., Ratliff T. et al. Measurement of prostate-specific antigen in serum a screening test for prostate cancer. N Engl J Med 1991;324: 1156—61.2. Catalona W., Smith D., Ratliff T. et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948—54.Catalona W., Smith D., Ratliff T. et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948—54.3. D’Amico A.V., Chen M.N., Roehl K.A., Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351(2):125—35.D’Amico A.V., Chen M.N., Roehl K.A., Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351(2):125—35.4. D’Amico A.V., Hanks G.E. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 1993;72(9):2638—43.D’Amico A.V., Hanks G.E. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 1993;72(9):2638—43.5. Gebbaulet A., Potter R., Mazeron J.J. et al. The GEC ESTRO Handbook of brachytherapy. Belgium, ACCO; 2002.Gebbaulet A., Potter R., Mazeron J.J. et al. The GEC ESTRO Handbook of brachytherapy. Belgium, ACCO; 2002.6. Koutrouvelis P. Prostate cancer: What a man should know. URO-Radiology prostate institute, 2005.Koutrouvelis P. Prostate cancer: What a man should know. URO-Radiology prostate institute, 2005.7. Christensson A., Laurell B., Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755—63.Christensson A., Laurell B., Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755—63.8. Pound C.R., Partin A.W., Eisenberger M.A. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-7.Pound C.R., Partin A.W., Eisenberger M.A. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-7.9. D’Amico A.V., Moul J.W., Carroll P.R. et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95(18):1376—83.D’Amico A.V., Moul J.W., Carroll P.R. et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95(18):1376—83.10. D’Amico A.V., Whittington R., Malkowicz S.D. et al. A method for determining a prostate-specific antigen cure after radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:473—77.D’Amico A.V., Whittington R., Malkowicz S.D. et al. A method for determining a prostate-specific antigen cure after radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:473—77.11. Geist R.W. Reference range for prostate-specific antigen levels after external beam radiation therapy for adenocarcinoma of the prostate. J Urol 1995;45:1016—21.Geist R.W. Reference range for prostate-specific antigen levels after external beam radiation therapy for adenocarcinoma of the prostate. J Urol 1995;45:1016—21.12. Zagars G.K., von Eschenbach A.C. Prostate-specific antigen: an important marker for prostate cancer treated by external beam radiation therapy. Cancer 1993;72:538—48.Zagars G.K., von Eschenbach A.C. Prostate-specific antigen: an important marker for prostate cancer treated by external beam radiation therapy. Cancer 1993;72:538—48.